1xbetÍøÒ³°æ

MERS-CoVÊÇ2012ÄêÔÚÖж«µØÇøÊ×ÏÈ·¢ÏÖµÄÒ»ÖÖÐÂÐ͹Ú×´²¡¶¾£¬Óë2003Äê·¢ÏÖµÄÑÏÖؼ±ÐÔºôÎüµÀ×ÛºÏÕ÷¹Ú×´²¡¶¾£¨SARS-CoV£©Í¬ÊôÓڦ¹Ú×´²¡¶¾¡£MERS-CoVÄܹ»Òý·¢ÑÏÖصÄÈËÀàºôÎüϵͳ¼²²¡£¬ÆäÖÂËÀÂʸߴï36%£¬Ä¿Ç°ÉÐÎÞÕë¶Ô¸Ã²¡¶¾µÄÔ¤·ÀÐÔÒßÃçºÍÌØЧµÄÖÎÁÆÊֶΡ£´Ó2012ÄêÖÁ½ñ£¬ÕÅÁÖçùºÍÍõÐÂȪÁ½¸ö¿ÎÌâ×éͨÁ¦ºÏ×÷£¬ÔÚMERS-CoVÏà¹ØµÄÑо¿ÖÐÈ¡µÃÁËһϵÁеÄÍ»³ö³É¹û¡£Á½¸ö¿ÎÌâ×鹲ͬ½âÎöÁËMERS-CoV RBDÓëÆäÊÜÌåµÄ½á¹¹£¨Wang, N. et al. Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4. Cell research 23, 986-993, doi:10.1038/cr.2013.92 (2013)£©£¬¹²Í¬·ÖÀëºÍ¼ø¶¨Á˸ßЧ¿¹MERS-CoVÈËÔ´µ¥¿Ë¡¿¹Ìå £¨MERS-4ºÍMERS-27£©£¨Jiang, L. et al. Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein. Science translational medicine 6, 234ra259, doi:10.1126/scitranslmed.3008140 (2014)£©£¬²¢Ð­Á¦¶ÔÆäÖÐÒ»¸ö¿¹Ì壨MERS-27£©µÄ±íλÒÔ¼°ÖкͻúÖƽøÐÐÑо¿£¨Yu, X. et al. Structural basis for the neutralization of MERS-CoV by a human monoclonal antibody MERS-27. Scientific reports 5, 13133, doi:10.1038/srep13133 (2015)£©¡£

´Ë´Î±¨µÀµÄÑо¿³É¹û£¬ÊÇÕÅÁÖçùºÍÍõÐÂȪÁ½¸ö¿ÎÌâ×é×îеĺÏ×÷²ú³ö¡£ÀûÓýṹÉúÎïѧѧµÄ·½·¨£¬½âÎöÁËRBDÓë¸ßЧµ¥¿Ë¡¿¹ÌåMERS-4¸´ºÏÎïµÄ¾§Ìå½á¹¹£¬½ÒʾÆä¶ÀÌصÄʶ±ð±íλºÍÖкÍ×÷ÓûúÖÆ¡£ÓëÒѾ­±¨µÀµÄ¿¹Ìå±È½Ï£¬MERS-4²¢²»ÊÇÖ±½ÓÓëÊÜÌ徺Õù½áºÏRBD·¢»ÓÆäÖкÍ×÷Ó㬶øÊÇͨ¹ýÓëRBD½áºÏµ¼ÖÂÆäÖÐÒ»¶ÎloopµÄ¹¹Ïó·¢ÉúÁ˽ϴóµÄ±ä»¯£¬½ø¶øÆÆ»µÁËRBDÓëÊÜÌåʶ±ðµÄ¹Ø¼üÇøÓò£¬¼ä½ÓµÄÐÐʹÆ俹²¡¶¾¹¦ÄÜ¡£ ´ËÍ⣬MERS-4¶Àµ½µÄʶ±ð±íλºÍÖкͻúÖÆʹËüÄܹ»ÓëÆäËü¿¹MERS-CoV¿¹Ìå²úÉúЭͬ×÷Óã¬Ìá¸ß¿¹²¡¶¾»îÐԺ͹ãÆ×ÐÔ£¬ÕâΪ¿¹ÌåÒ©ÎïÑз¢ÌṩÁËȫеÄÑ¡Ôñ¡£

¸ÃÑо¿µÄͨѶ×÷ÕßΪ1xbetÍøÒ³°æÕÅÁÖçù½ÌÊÚºÍÉúÃü¿ÆѧѧԺÍõÐÂȪ½ÌÊÚ£¬ÉúÃü¿ÆѧѧԺ²©Ê¿ÉúÕÅÉ­Ñà¡¢1xbetÍøÒ³°æ²©Ê¿ÉúÖÜÅÎÅκÍÉúÃü¿ÆѧѧԺ²©Ê¿ÉúÍõÅô·ÉΪ¹²Í¬µÚÒ»×÷Õß¡£¸ÃÑо¿µÃµ½Á˹ú¼Ò×ÔÈ»¿Æѧ»ù½ð¡¢¿Æ¼¼²¿ÖصãÑз¢ÏîÄ¿¡¢±È¶û¼°Ã·ÁÕ´ï¸Ç´Ä»ù½ðµÈµÄ×ÊÖú¡£

MERS-4ÓëRBD¸´ºÏÎï½á¹¹

¡òÂÛÎÄÁ´½Ó£º

https://www.cell.com/cell-reports/fulltext/S2211-1247(18)30951-3